Fig. 2. Tumor growth patterns of preventive vaccination of CT26-4-1BBL.
Before subcutaneous implantation of CT26-WT tumor cells (2×105 cell/100 μL PBS) into the left flank of each Balb/c mouse, doxorubicin-treated CT26-beta-gal and CT26-4-1BBL cells were used to vaccinate mouse three times every third days. Three days after the last tumor cell vaccination, CT26-WT tumor cells were administered. Tumor size was measured every third day.
© 2022 Biomed Sci Letters
